Conclusions
The current study demonstrated that sevoflurane upregulated GLUT1, MPC1, and GLUD1 expressions of ovarian cancer cells, while propofol downregulated the expressions of these molecules. These regulations by sevoflurane or propofol on ovarian cancer cells led to different metabolic features. The upregulated GLUT1 expression and, in turn, increased glucose uptake after sevoflurane exposure resulted in a decreased expression of PEDF. In opposite, an increased expression of PEDF was identified after propofol treatment. Furthermore, in contrast to propofol, sevoflurane upregulated Erk1/2 pathway, HIF-1α, CXCL12 and CXCR4 expressions through PEDF inhibition per se . In summary, the profiling alterations of molecular and metabolic modulations found in the present study indicate the pro- and anti-tumour properties of sevoflurane and propofol, respectively. The translational value of these is subjected to study further in clinical settings.